Celcuity Inc. (CELC)
CELCDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 2 past
PDUFA — gedatolisib
Celcuity is expanding the VIKTORIA-2 trial while awaiting an FDA decision on gedatolisib expected on July 17, 2026.
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Breast Cancer
Gedatolisib
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Palbociclib
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant | Phase 3 | Breast Cancer | - | - |
Gedatolisib | Phase 3 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | - | - |
Palbociclib | Phase 3 | Breast Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Celcuity Inc. (CELC)'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Celcuity Inc. (CELC)'s (CELC) pipeline across Phase 3. Its lead program is Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celcuity Inc. (CELC)'s next FDA catalyst?→
Celcuity Inc. (CELC)'s (CELC) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELC biotech catalysts?→
Add CELC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celcuity Inc. (CELC)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.